ArticleOncotarget2018

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Wei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.